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Abstract
Background: Analysis of the chromosomal background upon which a mutation occurs can be
used to reconstruct the origins of specific disease-causing mutations. The relatively common BRCA1
mutation, 1135insA, has been previously identified as a Norwegian founder mutation. We
performed haplotype analysis of individuals from breast and ovarian cancer families from four
different ethnic backgrounds who had been identified as carriers of the BRCA1: 1135insA mutation.
Methods: Four microsatellite markers (D17S855, D17S1322, D17S1323 and D17S1325) located
within or near the BRCA1 gene were genotyped in mutation carriers from 6 families of French
Canadian, Italian and Dutch descent. Haplotypes were inferred from the genotype data and
compared between these families and with the previously reported Norwegian founder haplotype.
Results: The 1135insA mutation was found to occur on three distinct haplotype backgrounds. The
families from Norway shared a distinct haplotype while the families of French Canadian, Italian, and
Dutch descent were found to occur on one of two additional, distinct backgrounds.
Conclusion: Our results indicate that while the Norwegian haplotype including 1135insA
represents an ancient Norwegian mutation, the same mutation has occurred independently in the
other populations examined. In centres where targeted mutation testing is performed, exclusively
or prior to gene sequencing, our findings suggest that this recurring mutation should be included
in targeted mutation panels, irrespective of the ethnic origin of the persons tested.
Background
Analysis of the chromosomal background upon which a
mutation occurs can be used to reconstruct the origins of
specific disease-causing mutations. Mutations that are
seen repeatedly on a common haplotype are likely to have
descended from a common ancestor, and are referred to as
"founder mutations". Several founder mutations of the
breast and ovarian cancer susceptibility gene BRCA1 have
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tries, including families of Ashkenazi Jewish (187delAG,
5385insC) [1], French Canadian (C4446T, 2953del3+C)
[2,3], Dutch (2804delAA and Alu-mediated deletions
encompassing exons 13 and 22) [4,5], and Polish
(5385insC, C61G, 4153delA) [6] origins. The BRCA1
mutation 1135insA (HGVS nomenclature:
c.1135_1136insA) is a frameshift mutation occurring in
exon 11. It has previously been identified as one of four
founder mutations originating from the Eastern popula-
tion of Norway [7,8]. In one series, approximately 1% of
Norwegian women under the age of 70 years with ovarian
cancer carried this mutation [9] and it accounts for ~20%
of all BRCA1/2 mutation carriers demonstrated by DNA
testing today in Norway (Møller, unpublished data). This
mutation appears on an ancient haplotype, and the age of
the 1135insA mutation has not yet been determined. All
tested Norwegian individuals with the 1135insA muta-
tion carry the same flanking markers (Møller, unpub-
lished data).
In contrast to other Norwegian founder mutations, the
1135insA mutation has also been reported in other ethnic
groups. The mutation has been catalogued 44 times to
date in the Breast Cancer Information Core (BIC) data-
base [10] and has been reported to occur in populations
throughout Europe including Spain, Norway, the Nether-
lands, Austria, Italy, as well as in Latin America and North
America. These observations raise the question whether
BRCA1: 1135insA is an ancient mutation that has arisen
once, or whether it has occurred several times in human
history. The issue is relevant when ethnic-specific muta-
tion panels are used as a pre-screen prior to complete
exon-by-exon evaluation of BRCA1/2. To address this
question, we performed haplotype analysis of the BRCA1
region in unrelated carrier families of Norwegian, Italian,
French Canadian, and Dutch descent.
Methods
Families containing individuals carrying the
BRCA1:1135insA mutation were recruited into the study
via high-risk cancer genetics clinics at McGill University,
Montreal, Quebec, Canada, VU University Medical Center
and the National Cancer Institute, Amsterdam, The Neth-
erlands, and The Department of Cancer Genetics, Olso,
Norway. Appropriate institutional informed consent
guidelines were followed for all recruited patients. All
mutation identification was performed by direct sequenc-
ing in the laboratories of the primary investigators at
McGill University, Montreal; the National Cancer Insti-
tute, Amsterdam and Haukeland University Hospital, Ber-
gen. Polymorphic microsatellite repeat markers located
within (D17S855, D17S1322, D17S1323) and adjacent
to (D17S1325) the BRCA1 locus were used for haplotype
analysis. We amplified 100ng of genomic DNA from each
subject by PCR for each marker using radioactively
Table 1: Haplotype analysis of unrelated, BRCA1 1135insA carriers
Marker Norway B856 B050 NKI Mon270 MonDS Mon1467
D17S1325 218 216 216 216 216 198 198
D17S1323 162 158 158 158 158 150 150
D17S1322 131 125 125 125 125 122 122
D17S855 150 146 146 146 146 150 150
Norway: Six Norwegian families [8]
B856, B050, NK1: Dutch families (Amsterdam)
Mon270, MonDS: Italian families (Montreal)
Mon1467: French Canadian (Montreal)
Table 2: Primers used to generate the haplotype
Marker Chromosome 17 
position
Forward Primer Reverse Primer Tm (°C) Other
D17S855 38,458,470 GGATGGCCTTTTA
GAAAGTGG
ACACAGACTTGTC
CTACTGCC
57 5 % DMSO†
D17S1322 38,465,161 CTAGCCTGGGCAA
CAAACGA
GCAGGAAGCAGG
AATGGAAC
60 --
D17S1323 38,491,793 TAGGAGATGGATT
ATTGGTG
AAGCAACTTTGCA
ATGAGTG
60 --
D17S1325 38,891,165 AAAGGTGGCAATT
CACAGTTG
GTGATAAAACTCA
GTGGTACTC
65-55* 1× Q solution
All reactions were amplified for 35 cycles [30s@95°C, 30s@Tm, 30s@72°C] and contained 200 uM dCTP/dGTP/dTTP, 24 uM dATP, 10 uCi α35S-
dATP, 1× PCR buffer and 0.5 U of HotStar Taq DNA polymerase (QIAGEN). †Dimethyl Sulfoxide. *Tm starting at 65°C and decreasing by 1°C per 
cycle for 10 cycles, followed by 25 cycles at 55°C; Q solution from QIAGEN.Page 2 of 4
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and PCR conditions are given in Table 2). PCR products
were separated on 5% acrylamide/urea denaturing gels at
70W for 1h45 and alleles were visualized by autoradiog-
raphy.
Results
Clinical description
Haplotype analysis was performed on selected cases from
three families recruited from the Hereditary Cancer Clinic
of McGill University in Montreal (2 Italian, 1 French
Canadian), and three Dutch families from the Nether-
lands Cancer Institute (NKI) in Amsterdam. Haplotype
analysis was previously done in Norway on six families
[8]. The index patients were referred because of a personal
and/or family history of breast or ovarian cancer and were
subsequently found to be carriers of the BRCA1: 1135insA
mutation. Although not discussed above, the family histo-
ries of these cases are consistent with this mutation being
highly penetrant for both breast and ovarian cancer. The
family histories of the Norwegian families have been
described previously [8].
Haplotype analysis
The results of the haplotype analyses are shown in Table
1. The 1135insA mutation was found to occur on three
distinct haplotype backgrounds. The families from Nor-
way had a unique haplotype (218-162-131-150). The
three Dutch families shared a common haplotype (216-
158-125-146), which was also found in one Italian family
from Montreal. The remaining two families from Mon-
treal – one family of French Canadian descent and the
other of Italian descent – shared a third distinct haplotype
(198-150-122-150).
Discussion
The unique haplotype common to all 6 Norwegian fami-
lies (218-162-131-150) indicates 1135insA is an ancient
founder mutation in the Norwegian population. The
Netherlands contained a major port during the Middle
Ages with outposts to ports elsewhere in Europe. By the
seventeenth century, Amsterdam was the biggest trading
port of northern commodities and grain to the Mediterra-
nean [12]. One can hypothesize that these trade routes are
one means by which a Norwegian founder mutation, on
its original haplotype, may have been passed to various
Mediterranean countries and hence to North America.
Identification of two other, clearly distinct haplotypes in
the families examined here suggests, however, that the
mutation likely occurred independently in other popula-
tions.
In the BIC database [10], the 1135insA mutation is the
12th most common frameshift mutation occurring in
BRCA1. Since our results suggest it does not have a single
origin, it may be a relative "hot spot" within the BRCA1
gene. Recombination events or marker mutations could
theoretically account for haplotype divergence from a sin-
gle, original haplotype but are not likely explanations
here. Marker D17S855 in intron 20 is only 6.7 kb from
D17S1322 in intron 19, and D17S1322 is 26 kb from
D17S1323 in intron 12. Markers in such close proximity
are unlikely to undergo extensive recombination events.
While recombination could conceivably have occurred
between D17S1325, located 400 kb upstream from
D171323, and the intragenic markers, the haplotypes
observed in our families are not consistent with this sce-
nario. In particular, recombination suppression seems to
be present in the genomic region that includes BRCA1,
making recombination in this region an even more
unlikely explanation [13]. On the other hand, the DNA
sequence surrounding the mutation includes a run of
seven consecutive adenines. BRCA1:1135insA is an inser-
tion of one A anywhere in the poly-A area in which it
occurs – the position 1135 is but a convention for nomen-
clature. This poly-A region may thus create a hot-spot
within BRCA1 for replication errors. Alternatively, the
same poly-A stretch may have induced repetitive gene
conversions or cross-overs.
The BRCA2 mutation 8765delAG is another example of
an "ancient" mutation that has been shown to have
recurred in different populations. First described as a
founder mutation in Sardinia [14], it has been found on
different haplotype backgrounds in different populations,
including French Canadians and Yemenite Jews [15]. The
mutation occurs within a stretch of DNA where 4 consec-
utive AGs can be found. It is likely that the genomic con-
text in which the BRCA1: 1135insA and BRCA2:
8765delAG mutations occur favours errors of small inser-
tions and deletions.
Conclusion
We set out to determine whether BRCA1: 1135insA is an
ancient mutation that has arisen once, or whether it has
recurred several times in human history. Our finding that
1135insA exists on several, clearly distinct haplotypes and
the fact that it is found in a homopolymer tract suggests it
may have appeared independently several times in the
human genome. A clinically relevant implication of our
findings is that this recurrent mutation should probably
be included in targeted BRCA1 mutation screening panels
in any population, irrespective of ethnic origin. When the
ethnic origin is clearly defined, founder mutation panels
can, and are used in several centres. A "pre-screen" based
on the most frequent BRCA1/2 mutations seen in the BIC
could also be considered as a first step, prior to complete
gene sequence analysis.Page 3 of 4
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